메뉴 건너뛰기
Journal of Thoracic Oncology
Volumn 6, Issue 2, 2011, Pages 239-240
Editorial: You just can't call it lung cancer anymore
Author keywords

[No Author keywords available]
Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PEMETREXED;
EID: 79551543876     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31820bf5b8     Document Type: Editorial
Times cited : (5)
References (7)
  • 1
    • 79551563284 scopus 로고    scopus 로고
    • IASLC/ATS/ERS international multidisciplinary classification of lung adenocarcinoma
    • Travis W. IASLC/ATS/ERS international multidisciplinary classification of lung adenocarcinoma. J Thorac Onc 2011;6:244-285.
    • (2011) J. Thorac. Onc , vol.6 , pp. 244-285
    • Travis, W.1
  • 2
    • 78049425319 scopus 로고    scopus 로고
    • Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
    • Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-1703.
    • (2010) N. Engl. J. Med. , vol.363 , pp. 1693-1703
    • Kwak, E.L.1    Bang, Y.J.2    Camidge, D.R.3
  • 3
    • 2342471392 scopus 로고    scopus 로고
    • Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib
    • Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
    • (2004) N. Engl. J. Med. , vol.350 , pp. 2129-2139
    • Lynch, T.J.1    Bell, D.W.2    Sordella, R.3
  • 4
    • 70350225538 scopus 로고    scopus 로고
    • Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase 3 study
    • Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:1432-1440.
    • (2009) Lancet , vol.374 , pp. 1432-1440
    • Ciuleanu, T.1    Brodowicz, T.2    Zielinski, C.3
  • 5
    • 75249084998 scopus 로고    scopus 로고
    • Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer
    • Mok TS, Wu YL, Yu CJ, et al. Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2009;27:5080-5087.
    • (2009) J. Clin. Oncol. , vol.27 , pp. 5080-5087
    • Mok, T.S.1    Wu, Y.L.2    Yu, C.J.3
  • 6
    • 49049089802 scopus 로고    scopus 로고
    • Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
    • Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
    • (2008) J. Clin. Oncol. , vol.26 , pp. 3543-3551
    • Scagliotti, G.V.1    Parikh, P.2    Von Pawel, J.3
  • 7
    • 22044453790 scopus 로고    scopus 로고
    • Erlotinib in lung cancer-molecular and clinical predictors of outcome
    • Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-144.
    • (2005) N. Engl. J. Med. , vol.353 , pp. 133-144
    • Tsao, M.S.1    Sakurada, A.2    Cutz, J.C.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.